Validation of breast cancer as a risk factor for anxiety and depression: Insights from Mendelian randomization analysis.
10.1016/j.jpha.2025.101378
- Author:
Guannan HE
1
;
Man XI
1
;
Tianhao ZHANG
1
;
Shuang WANG
1
;
Gang LIU
1
Author Information
1. Department of Anesthesiology, First Affiliated Hospital, China Medical University, Shenyang, 110001, China.
- Publication Type:Journal Article
- Keywords:
Anxiety and depression behaviors;
Astrocytes;
Breast cancer;
High-throughput transcriptome sequencing;
Ketamine-loaded lipid nanoparticles;
Mendelian randomization analysis;
Nrf2;
Single-cell transcriptome sequencing
- From:
Journal of Pharmaceutical Analysis
2025;15(9):101378-101378
- CountryChina
- Language:English
-
Abstract:
This study employed Mendelian randomization (MR) analysis to confirm the association between breast cancer and the risk of anxiety and depression, and to explore the molecular mechanisms by which lipid nanoparticles of ketamine (LNP@Ket) modulate these behaviors in a mouse model of breast cancer. Through single-cell transcriptomic analysis, the study aimed to clarify nuclear factor erythroid 2-related factor 2 (Nrf2)'s role in the development of anxiety and depression in these mice. Analysis of patient data from genome-wide association study (GWAS) databases supported the link between breast cancer, anxiety, and depression. In vivo experiments demonstrated that treating breast cancer mice with LNP@Ket significantly reduced anxiety and depression behaviors. The synthesis of LNP@Ket and its subsequent analysis highlighted its inhibitory effects on these behaviors. Single-cell transcriptomic sequencing identified key cells and genes affected by LNP@Ket treatment, particularly emphasizing Nrf2. Upregulation of Nrf2 in astrocytes increased the expression of antioxidant enzymes and reduced pro-inflammatory cytokines, alleviating anxiety and depression symptoms by inhibiting neuroinflammation and neurodegeneration. This comprehensive study highlights the pivotal role of Nrf2 in the therapeutic efficacy of LNP@Ket for treating anxiety and depression in breast cancer mice.
